Ardelyx Inc (ARDX)

NASDAQ
1.310
-0.030(-2.24%)
After Hours
1.320
+0.010(+0.763%)
- Real-time Data
  • Volume:
    7,757,542
  • Bid/Ask:
    1.310/1.320
  • Day's Range:
    1.290 - 1.360

ARDX Overview

Prev. Close
1.34
Day's Range
1.29-1.36
Revenue
12.41M
Open
1.357
52 wk Range
1.25-9.19
EPS
-1.31
Volume
7,757,542
Market Cap
135.09M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
10,453,995
P/E Ratio
-
Beta
1.85
1-Year Change
-78.38%
Shares Outstanding
103,119,010
Next Earnings Date
Nov 10, 2021
What is your sentiment on Ardelyx Inc?
or
Market is currently closed. Voting is open during market hours.

Ardelyx Inc News

Ardelyx Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuySellSellStrong Sell
Technical IndicatorsNeutralBuyStrong BuyStrong SellStrong Sell
SummaryNeutralBuyNeutralStrong SellStrong Sell

Ardelyx Inc Company Profile

Ardelyx Inc Company Profile

Employees
129

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Read More
  • Yes PLEASE!
    0
    • Let’s go to 3,7
      0
      • when shall be next FDA approval? in current year or next year?
        0
        • To $30! 🚀🚀🚀Just waiting on the FDA, theyre slower than molassis unless their dealing with big money and political pressure. With enough bribes, they’ll approve the clinical use of snake oil.
          0
          • 4 BIOTECH STOCKS FACING FDA REJECTION!Is it a full stop or a pause to their journey?https://www.reddit.com/r/MicrocapStocksRun/comments/palt5t/4_biotech_stocks_facing_fda_rejection/?utm_source=share&utm_medium=web2x&context=3
            0
            • I’ll keep buying more, this company will 10x in the medium to long term.
              0
              • do you mean medium - 5 years and long term -10 years?
                0
            • $$$%
              1
              • Enticing prices, lol. The lawyers are in collusion for the shorts and hedgies, they dont give an FF about the retail investors that lost over $6/ share two weeks ago. Its time to pump this stock to $10, the price it deserves. Tenapenor has shown effectiveness in reducing serum phosphorus levels in patients suffering from chrinic kidney disease undergoing renal dialysis. If anyone should be prosecuted, it should be the greedy hedgefunds, and corrupt FDA for preventing an effective drug from entering the pharmaceutical market.
                0
                • about to boom
                  0
                  • 2.50+ this week
                    0
                    • how??
                      0
                  • the bottom line is 1.0
                    0
                    • even much sweeter invitations for longs to come in :-)
                      0
                  • look like 1.90 is the bottom ...below will be the black Friday discount price glta :-)
                    0
                    • I will buy more soon with this 90 % off sale.
                      0
                      • this oversold price $2 is not going to be there for long :-)
                        0
                        • last time this company was in the 1.80s was back in 2017 so not this is not the price for this company so soon 5s and then 8s if good news comes in guarantee
                          0
                          • why is the market not moving. trying to purchase stock
                            0
                            • funcking stock
                              0
                              • FDA found problems with their kidney drugs ie the drop. Will wait for potential good news
                                0
                                • Time to buy ?
                                  0
                                • if you're buying, you're gambling
                                  0
                              • Buy ! All in
                                0
                                • sdfsdf
                                  0
                                  • Not back up , more drop
                                    0
                                    • It will come back. Buy while it's so cheap.
                                      0
                                      • Why is it down so much? Any news?
                                        0
                                        • my average 8.8 soon , when goes up.
                                          0
                                          • yes. hurry and buy while it's low.
                                            0
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.